Reply to: Therapeutic Strategy Concerns for <i>BRAF</i> V600E–Mutated Differentiated Thyroid Cancer

N Nabil F. Saba N Nofisat Ismaila (American Society of Clinical Oncology (ASCO), Alexandria, VA, US) F Francis Worden B Beth M. Beadle (Nabil F. Saba, MD, Emory University, Atlanta, GA, Nofisat Ismaila, MD, American Society of Clinical Oncology (ASCO), Alexandria, VA, Francis Worden, MD, University of Michigan Rogel Cancer Center, Ann Arbor, MI, Beth M. Beadle, MD, Stanford University, Stanford, CA)

Article Details

Volume / Issue Vol. 1, Issue 1
Published August 06, 2026
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (4)

N

Nabil F. Saba

N

Nofisat Ismaila

American Society of Clinical Oncology (ASCO), Alexandria, VA, US

F

Francis Worden

B

Beth M. Beadle

Nabil F. Saba, MD, Emory University, Atlanta, GA, Nofisat Ismaila, MD, American Society of Clinical Oncology (ASCO), Alexandria, VA, Francis Worden, MD, University of Michigan Rogel Cancer Center, Ann Arbor, MI, Beth M. Beadle, MD, Stanford University, Stanford, CA